Prostatype Genomics AB (publ) (PROGEN.ST)

SEK 2.15

(12.57%)

Net Debt Summary of Prostatype Genomics AB (publ)

Prostatype Genomics AB (publ)'s latest annual net debt in 2023 was -2.61 Million SEK , up 33.7% from previous year.
Prostatype Genomics AB (publ)'s latest quarterly net debt in 2024 Q1 was -1.78 Million SEK , down -119.87% from previous quarter.
Prostatype Genomics AB (publ) reported annual net debt of -3.94 Million SEK in 2022, up 53.93% from previous year.
Prostatype Genomics AB (publ) reported annual net debt of -8.56 Million SEK in 2021, up 40.52% from previous year.
Prostatype Genomics AB (publ) reported quarterly net debt of -1.78 Million SEK for 2024 Q2, down 0.0% from previous quarter.
Prostatype Genomics AB (publ) reported quarterly net debt of 8.98 Million SEK for 2023 Q4, down 0.0% from previous quarter.

Annual Net Debt Chart of Prostatype Genomics AB (publ) (2023 - 2015)

Historical Annual Net Debt of Prostatype Genomics AB (publ) (2023 - 2015)

Year	Net Debt	Net Debt Growth
2023	-2.61 Million SEK	33.7%
2022	-3.94 Million SEK	53.93%
2021	-8.56 Million SEK	40.52%
2020	-14.39 Million SEK	0.0%
2018	4.16 Million SEK	204.22%
2017	1.36 Million SEK	116.3%
2016	-8.39 Million SEK	-711.39%
2015	1.37 Million SEK	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	-1.78 Million SEK	-119.87%
2024 Q2	-1.78 Million SEK	0.0%
2023 Q4	8.98 Million SEK	0.0%
2023 FY	-2.61 Million SEK	33.7%
2023 Q3	8.98 Million SEK	181.47%
2023 Q2	-11.02 Million SEK	-2206.85%
2023 Q1	523.45 Thousand SEK	113.27%
2022 Q4	-3.94 Million SEK	72.41%
2022 Q3	-14.29 Million SEK	-5700.59%
2022 FY	-3.94 Million SEK	53.93%
2022 Q2	255.22 Thousand SEK	109.25%
2022 Q1	-2.75 Million SEK	67.77%
2021 FY	-8.56 Million SEK	40.52%
2021 Q2	-6.19 Million SEK	31.87%
2021 Q1	-9.08 Million SEK	36.88%
2021 Q4	-8.56 Million SEK	65.99%
2021 Q3	-25.17 Million SEK	-306.73%
2020 Q3	1.23 Million SEK	-85.65%
2020 Q2	8.58 Million SEK	0.0%
2020 FY	-14.39 Million SEK	0.0%
2020 Q4	-14.39 Million SEK	-1268.97%
2019 Q3	1.17 Million SEK	0.0%
2018 FY	4.16 Million SEK	204.22%
2017 FY	1.36 Million SEK	116.3%
2016 FY	-8.39 Million SEK	-711.39%
2015 FY	1.37 Million SEK	0.0%

Peer Net Debt Comparison of Prostatype Genomics AB (publ)

Name	Net Debt	Net Debt Difference
AroCell AB (publ)	-50.72 Million SEK	94.845%
Devyser Diagnostics AB (publ)	-188.09 Million SEK	98.61%
Immunovia AB (publ)	-72.5 Million SEK	96.393%
SenzaGen AB	-15.95 Million SEK	83.606%
Spermosens AB	5.02 Million SEK	152.04%